[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lip-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lip-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100100354","identification-of-secreted-markers-for-tumor-hypoxia-in-patients-with-head-and-neck-or-lung-cancers-100100354",false,"NCT00568490","Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers","Inclusion Criteria:\n\n* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.\n* Able to sign a Stanford IRB approved consent form\n\nExclusion criteria:\n\n* Refuse or unable to sign an IRB approved consent form.\n* Refuse to be contacted in the future for follow up.","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.",[23,24,25,26,27],"Head and Neck Cancer","Lung Cancer","Lip Cancer","Lip Neoplasms","Head and Neck Cancers","RECRUITING","2026-06-29",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":32},"1998-09-01",{"date":36,"type":19},"2027-06-30",{"name":38,"class":39},"Stanford University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":20,"phases":4,"briefSummary":54,"conditions":55,"keywords":104,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"19 Years","110 Years",{"count":52,"type":19},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[56,57,24,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,25,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103],"Pancreatic Cancer","Thyroid Cancer","Esophageal Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Anal Cancer","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Liver Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Kidney Cancer","Penile Cancer","Prostate Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Melanoma","Sarcoma","Unknown Primary Tumor","Multiple Myeloma","Ovarian Cancer","Endometrial Cancer","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[56,57,105,106,107,108,109,110,111,112,92,113,102,103],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":29,"type":32},{"date":117,"type":32},"2013-11-01",{"date":119,"type":19},"2099-12",{"name":121,"class":39},"University of Nebraska",42,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":40},"100503589","microbiome-in-head-and-neck-squamous-cell-carcinoma-100503589","NCT05837221","Microbiome in Head and Neck Squamous Cell Carcinoma","Role of Human Microbiome in Head and Neck Cancer","Inclusion Criteria:\n\n1. Subjects equal to or above the age of 18.\n2. Patients who are seen and evaluated by a provider within the adult Otolaryngology clinic at the University of Colorado Health.\n3. Patients that present with a diagnosis of OSCC.\n4. An equal number of age-matched patients who are visiting the clinic for reasons other than OSCC diagnoses, as the control group.\n5. Ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Subjects under the age of 18 or over the age of 100\n2. Subjects unwilling to particiapte","100 Years",{"count":132,"type":19},60,"This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.",[23,25,135,136],"Oral Cancer","Pharynx Cancer","2026-02-20",{"date":139,"type":32},"2026-02-24",{"date":141,"type":32},"2025-05-23",{"date":143,"type":19},"2028-10",{"name":145,"class":39},"University of Colorado, Denver"]